[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Rhea-AI Filing Summary

Gilead Sciences EVP Keeley M Cain Wettan reported routine equity compensation changes. On March 10, 2026, 1,246 restricted stock units converted into the same number of common shares, increasing her direct common stock holdings to 5,054 shares after 606 shares were withheld to cover taxes.

She also received 5,050 new restricted stock units and 18,885 non-qualified stock options exercisable at $148.56 per share, expiring in 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting quarterly at 6.25% until fully vested.

Insider Trade Summary

1,246 shares exercised/converted

Mixed 5 txns

Insider Cain Wettan Keeley M

Role EVP Gen Counsel, Legal & Comp

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	1,246	$0.00	--
Grant/Award	Restricted Stock Unit	5,050	$0.00	--
Grant/Award	Non-qualified Stock Option (Right to Buy)	18,885	$0.00	--
Exercise	Common Stock	1,246	$0.00	--
Tax Withholding	Common Stock	606	$148.56	$90K

Holdings After Transaction: Restricted Stock Unit — 15,536 shares (Direct); Non-qualified Stock Option (Right to Buy) — 18,885 shares (Direct); Common Stock — 5,660 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cain Wettan Keeley M

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Gen Counsel, Legal & Comp

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M		1,246	A	(1)	5,660	D
Common Stock	03/10/2026		F		606	D	$148.56	5,054	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/10/2026		M			1,246	(2)	(2)	Common Stock	1,246	(1)	15,536	D
Restricted Stock Unit	(1)	03/10/2026		A		5,050		(2)	(2)	Common Stock	5,050	(1)	20,586	D
Non-qualified Stock Option (Right to Buy)	$148.56	03/10/2026		A		18,885		(3)	03/10/2036	Common Stock	18,885	$0	18,885	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

3. The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Keeley M. Cain Wettan	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did GILD executive Keeley M Cain Wettan receive?

Keeley M Cain Wettan received new RSUs and stock options. She was granted 5,050 restricted stock units and 18,885 non-qualified stock options at an exercise price of $148.56 per share, all subject to a four-year vesting schedule.

How many Gilead (GILD) shares did the executive acquire on March 10, 2026?

She acquired 1,246 shares of Gilead common stock. These shares came from the vesting and conversion of 1,246 restricted stock units. After this and tax withholding, her direct common stock holdings totaled 5,054 shares.

What tax-related stock transaction occurred for the GILD executive?

606 Gilead shares were withheld for tax obligations. Following the RSU conversion, 606 common shares were disposed of at $148.56 per share to satisfy tax liabilities, a standard non-market transaction rather than an open-market sale.

What is the vesting schedule for the new GILD RSUs and options?

Both RSUs and options vest over four years. For each grant, 25% vests on the first anniversary of the grant date, and the remaining 75% vests in equal 6.25% quarterly installments until fully vested.

How many Gilead (GILD) options does the executive hold after these grants?

She holds 18,885 non-qualified stock options after the grant. These options allow purchase of 18,885 Gilead common shares at an exercise price of $148.56 per share, with an expiration date in 2036.

Did the GILD executive’s Form 4 show open-market buying or selling?

The Form 4 shows compensation-related acquisitions and tax withholding. Transactions included RSU vesting, new RSU and option grants, and shares withheld for taxes, with no open-market purchases or discretionary sales reported.